This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
We've just published the final set of Molecules of the Month for 2021, and now it's time to nominate your…
Article
1 year ago ●
1 min read
Context. BMS-986120 is an oral protease-activated receptor 4 (PAR4) inhibitor that was being developed for arterial thrombosis. PAR4 was long…
molecule
8 months ago ●
5 mins read
Dear Drug Hunter, It's gotten harder and harder to keep up with everything that's going on in the industry. From…
Article
1 year ago ●
4 mins read
Context. EZM0414 (Epizyme, Inc.) is an oral SETD2 inhibitor being developed for hematological malignancies. Although several genetic studies have proposed…
molecule
8 months ago ●
5 mins read
In Aug. 2021, immuno-oncology company, Trillium Therapeutics, was acquired by Pfizer for $2.3 billion, adding Trillium’s two CD47-targeting biologics, TTI-621 and…
Article
1 year ago ●
3 mins read
Context. DNL201 (Denali Therapeutics) is an oral, CNS-penetrating, ATP-competitive leucine-rich repeat kinase 2 (LRRK2) inhibitor being developed for Parkinson’s disease…
molecule
8 months ago ●
6 mins read
Load More
